Skip to main content

Table 2 Summary of adverse events recorded during the study

From: A randomized trial to monitor the efficacy and effectiveness by QT-NASBA of artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment and transmission control of uncomplicated Plasmodium falciparum malaria in western Kenya

Adverse event

DHA-PQP

ALN

P- value

Headache

43 (58.9%)

37 (50.7%)

0.318

Abdominal pain

25 (32.4%)

26 (35.6%)

0.862

Weakness

19 (26.0%)

30 (41.1%)

0.035

Anorexia

8 (10.9%)

10 (13.7%)

0.439

Diarrhea

9 (12.3%)

7 (9.6%)

0.785

Cough

16 (21.9%)

17 (23.3%)

0.843

Vomiting

11 (15.1%)

9 (12.3%)

0.806

Pruritis

4 (5.5%)

3 (4.1%)

0.698